Biogen Inc. (BIIB)

Biogen's stock experienced several notable events in the past six months. In October 2025, shares saw a 14% increase following the regulatory approval of Leqembi in China. On October 30, 2025, the company released its Q3 2025 earnings. On February 6, 2026, Biogen reported its Q4 and full-year 2025 financial results, exceeding expectations and reaching a new 52-week high. The FDA approved LEQEMBI intravenous maintenance dosing, and the BLA for subcutaneous maintenance dosing was accepted by the FDA. Filings for a higher dose regimen of SPINRAZA were also accepted by the FDA and EMA.

The demand for Biogen's products does not typically exhibit significant seasonality. Analysts anticipate a mid-single-digit percentage decline in total revenue for 2026 compared to 2025, indicating some ongoing demand challenges. This projected decline is not attributed to seasonal factors but rather to the evolving market dynamics, including competition for its older MS products, which are being offset by growth in newer therapies.

Biogen Inc. is a multinational biotechnology company focused on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its core focus is on neuroscience, with activities spanning multiple therapeutic areas, including multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease (AD), Friedreich's Ataxia, and postpartum depression. Major products include treatments for MS, SMA, AD, Friedreich's Ataxia, postpartum depression, plaque psoriasis, and biosimilars. Biogen also collaborates on therapies for conditions like non-Hodgkin's lymphoma and rheumatoid arthritis.

Biogen has a global presence with operations and commercial activities across North America, Europe, Japan, and other international markets. Its products are marketed globally, with significant operations in the U.S., Europe, and Asia. Recent regulatory approvals for Leqembi in China and Japan highlight its expanding international reach.

Over the past year, Biogen's brand reputation has been characterized by a growing confidence in the "New Biogen," reflecting a successful transition from its older multiple sclerosis (MS) drugs to a modern portfolio of neuro-innovations. This strategic shift has helped to silence critics who feared a permanent decline as the company's legacy MS business faces biosimilar competition. The successful commercialization of new products like Leqembi for Alzheimer's, Skyclarys for Friedreich's Ataxia, and Zurzuvae for postpartum depression has been crucial in bolstering its reputation and demonstrating its ability to deliver profitable new therapies.

Biogen's ownership is primarily institutional, with 88.98% held by institutional shareholders, 2.13% by Biogen insiders, and 8.89% by retail investors. Major institutional owners include Vanguard Group Inc., Primecap Management Co., Blackrock Inc., State Street Corp., Wellington Management Group LLP, Geode Capital Management LLC, Point72 Asset Management LP, Invesco Ltd., Morgan Stanley, and Aqr Capital Management LLC.